|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu
J, Ren ZG and Jiang GL: Metformin is associated with reduced risk
of pancreatic cancer in patients with type 2 diabetes mellitus: A
systematic review and meta-analysis. Diabetes Res Clin Pract.
106:19–26. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galeone C, Edefonti V, Parpinel M,
Leoncini E, Matsuo K, Talamini R, Olshan AF, Zevallos JP, Winn DM,
Jayaprakash V, et al: Folate intake and the risk of oral cavity and
pharyngeal cancer: A pooled analysis within the International Head
and Neck Cancer Epidemiology Consortium. Int J Cancer. 136:904–914.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang R, Zhang P, Wang H, Hou D, Li W,
Xiao G and Li C: Inhibitory effects of metformin at low
concentration on epithelial-mesenchymal transition of
CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther.
6:2622015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hua H, Kong Q, Zhang H, Wang J, Luo T and
Jiang Y: Targeting mTOR for cancer therapy. J Hematol Oncol.
12:712019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de la Cruz López KG, Toledo Guzmán ME,
Sánchez EO and García Carrancá A: mTORC1 as a Regulator of
Mitochondrial Functions and a Therapeutic Target in Cancer. Front
Oncol. 9:13732019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doan H, Parsons A, Devkumar S, Selvarajah
J, Miralles F and Carroll VA: HIF-mediated Suppression of DEPTOR
Confers Resistance to mTOR Kinase Inhibition in Renal Cancer.
iScience. 21:509–520. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam
D, Lee J, Lee SG, Yang WM, Um JY, et al: Ginkgolic acid inhibits
invasion and migration and TGF-β-induced EMT of lung cancer cells
through PI3K/Akt/mTOR inactivation. J Cell Physiol. 232:346–354.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deng J, Bai X, Feng X, Ni J, Beretov J,
Graham P and Li Y: Inhibition of PI3K/Akt/mTOR signaling pathway
alleviates ovarian cancer chemoresistance through reversing
epithelial-mesenchymal transition and decreasing cancer stem cell
marker expression. BMC Cancer. 19:6182019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Choi D, Kim CL, Kim JE, Mo JS and Jeong
HS: Hesperetin inhibit EMT in TGF-β treated podocyte by regulation
of mTOR pathway. Biochem Biophys Res Commun. 528:154–159. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo Y, Xiao Z, Yang L, Gao Y, Zhu Q, Hu L,
Huang D and Xu Q: Hypoxia-inducible factors in hepatocellular
carcinoma (Review). Oncol Rep. 43:3–15. 2020.PubMed/NCBI
|
|
12
|
Chen G, Feng W, Zhang S, Bian K, Yang Y,
Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer
via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res.
5:1423–1434. 2015.PubMed/NCBI
|
|
13
|
Hasan D, Gamen E, Abu Tarboush N, Ismail
Y, Pak O and Azab B: PKM2 and HIF-1α regulation in prostate cancer
cell lines. PLoS One. 13:e02037452018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin C, Ren Z, Yang X, Yang R, Chen Y, Liu
Z, Dai Z, Zhang Y, He Y, Zhang C, et al: Nerve growth factor
(NGF)-TrkA axis in head and neck squamous cell carcinoma triggers
EMT and confers resistance to the EGFR inhibitor erlotinib. Cancer
Lett. 472:81–96. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai HH, Li JN, Wang MY, Huang HY, Croce
CM, Sun HL, Lyu YJ, Kang JW, Chiu CF, Hung MC, et al: HIF-1α
promotes autophagic proteolysis of Dicer and enhances tumor
metastasis. J Clin Invest. 128:625–643. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li YH, Li XF, Liu JT, Wang H, Fan LL, Li J
and Sun GP: PKM2, a potential target for regulating cancer. Gene.
668:48–53. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heckman-Stoddard BM, DeCensi A,
Sahasrabuddhe VV and Ford LG: Repurposing metformin for the
prevention of cancer and cancer recurrence. Diabetologia.
60:1639–1647. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Q, Tong D, Liu G, Xu J, Do K, Geary K,
Zhang D, Zhang J, Zhang Y, Li Y, et al: Metformin reverses prostate
cancer resistance to enzalutamide by targeting TGF-β1/STAT3
axis-regulated EMT. Cell Death Dis. 8:e30072017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng K and Hao M: Metformin inhibits
TGF-β1-induced epithelial-to-mesenchymal transition via PKM2
relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells.
Int J Mol Sci. 17:E20002016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park JH, Kim YH, Park EH, Lee SJ, Kim H,
Kim A, Lee SB, Shim S, Jang H, Myung JK, et al: Effects of
metformin and phenformin on apoptosis and epithelial-mesenchymal
transition in chemoresistant rectal cancer. Cancer Sci.
110:2834–2845. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Joseph JP, Harishankar MK, Pillai AA and
Devi A: Hypoxia induced EMT: A review on the mechanism of tumor
progression and metastasis in OSCC. Oral Oncol. 80:23–32. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kong D, Zhang F, Shao J, Wu L, Zhang X,
Chen L, Lu Y and Zheng S: Curcumin inhibits cobalt chloride-induced
epithelial-to-mesenchymal transition associated with interference
with TGF-β/Smad signaling in hepatocytes. Lab Invest. 95:1234–1245.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S, Zhang J, Yang H, Wu C, Dang X and
Liu Y: Copper depletion inhibits CoCl2-induced aggressive phenotype
of MCF-7 cells via downregulation of HIF-1 and inhibition of
Snail/Twist-mediated epithelial-mesenchymal transition. Sci Rep.
5:124102015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Santi M, Baldelli G, Diotallevi A,
Galluzzi L, Schiavano GF and Brandi G: Metformin prevents cell
tumorigenesis through autophagy-related cell death. Sci Rep.
9:662019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abdel-Wahab AF, Mahmoud W and Al-Harizy
RM: Targeting glucose metabolism to suppress cancer progression:
Prospective of anti-glycolytic cancer therapy. Pharmacol Res.
150:1045112019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen H, Lin C, Lu C, Wang Y, Han R, Li L,
Hao S and He Y: Metformin-sensitized NSCLC cells to osimertinib via
AMPK-dependent autophagy inhibition. Clin Respir J. 13:781–790.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian
CN, Zhang J and Lu Y: Metformin targets multiple signaling pathways
in cancer. Chin J Cancer. 36:172017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quan C, Sun J, Lin Z, Jin T, Dong B, Meng
Z and Piao J: Ezrin promotes pancreatic cancer cell proliferation
and invasion through activating the Akt/mTOR pathway and inducing
YAP translocation. Cancer Manag Res. 11:6553–6566. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Esparza-López J, Alvarado-Muñoz JF,
Escobar-Arriaga E, Ulloa-Aguirre A and de Jesús Ibarra-Sánchez M:
Metformin reverses mesenchymal phenotype of primary breast cancer
cells through STAT3/NF-κB pathways. BMC Cancer. 19:7282019.
View Article : Google Scholar : PubMed/NCBI
|
